



**To:** All PCPs and IPAs  
**From:** IEHP – Provider Relations  
**Date:** April 13, 2022  
**Subject:** **COVID-19 “Test to Treat” Initiative**

---

---

The Biden-Harris Administration launched a new nationwide **COVID-19 Test to Treat** initiative to give all individuals quick access to free, lifesaving treatment for COVID-19.

These “**One-Stop Test to Treat**” sites include:

- Pharmacy-based clinics
- Federally Qualified Health Centers (FQHCs)
- Long-term care facilities

These locations provide individuals with testing and, if results are positive and treatments are appropriate, a prescription filled onsite by a health care provider for the following COVID-19 oral antiviral pills:

- Merck’s **LAGEVRIO (MOLNUIRAVIR)**
- Pfizer’s **PAXLOVID (NIRMATRELVIR / RITONAVIR)**.

Members may also bring COVID-19 positive results from another testing site or at-home test kits to designated “Test to Treat” sites to receive a prescription for needed oral anti-viral pills.

While Providers may continue to test Members and prescribe oral antiviral pills, Test to Treat locations provide time-sensitive medications in a one-stop shop for COVID-19 positive Members.

Testing sites can be located for our members who need urgent access to treatment by calling 1-800-232-0233 (TTY 1-888-720-7489) or via **Test to Treat Locator** <https://covid-19-test-to-treat-locator-dhhs.hub.arcgis.com/>

**For more information about COVID-19 Test to Treat, please visit:**  
<https://aspr.hhs.gov/TestToTreat/Documents/Fact-Sheet.pdf>

As a reminder, all communications sent by IEHP can also be found on our Provider portal at: [www.iehp.org](http://www.iehp.org) > For Providers > Plan Updates > Correspondence

If you have any questions, please do not hesitate to contact the IEHP Provider Relations Team at (909) 890-2054 or (866) 223-4347.